1. Home
  2. KMI vs ARGX Comparison

KMI vs ARGX Comparison

Compare KMI & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kinder Morgan Inc.

KMI

Kinder Morgan Inc.

HOLD

Current Price

$31.18

Market Cap

73.1B

Sector

Utilities

ML Signal

HOLD

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$1,021.03

Market Cap

58.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KMI
ARGX
Founded
1936
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Natural Gas Distribution
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.1B
58.4B
IPO Year
2010
2017

Fundamental Metrics

Financial Performance
Metric
KMI
ARGX
Price
$31.18
$1,021.03
Analyst Decision
Buy
Strong Buy
Analyst Count
16
19
Target Price
$33.69
$1,008.56
AVG Volume (30 Days)
9.7M
293.1K
Earning Date
04-22-2026
05-07-2026
Dividend Yield
3.74%
N/A
EPS Growth
17.09
N/A
EPS
0.82
N/A
Revenue
$16,937,000,000.00
N/A
Revenue This Year
$5.43
$44.39
Revenue Next Year
$4.52
$20.84
P/E Ratio
$37.80
$33.69
Revenue Growth
12.17
N/A
52 Week Low
$25.60
$661.85
52 Week High
$34.81
$1,058.69

Technical Indicators

Market Signals
Indicator
KMI
ARGX
Relative Strength Index (RSI) 41.14 68.00
Support Level $26.38 $830.58
Resistance Level $33.02 N/A
Average True Range (ATR) 0.68 27.02
MACD -0.09 16.17
Stochastic Oscillator 14.12 85.11

Price Performance

Historical Comparison
KMI
ARGX

About KMI Kinder Morgan Inc.

Kinder Morgan operates natural gas, crude oil, and refined products pipelines connecting producing regions to demand centers. It is principally involved in the gathering, storage, and transmission of natural gas across the continental United States. It also operates distribution centers for refined products along with the largest fleet of Jones Act-compliant tankers.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: